Controlled trials needed to prove efficacy and safety of convalescent plasma therapy in coronavirus disease 2019

Ann Allergy Asthma Immunol. 2021 Feb;126(2):122-123. doi: 10.1016/j.anai.2020.11.005. Epub 2020 Nov 5.
No abstract available

MeSH terms

  • COVID-19 / therapy*
  • COVID-19 Serotherapy
  • Humans
  • Immunization, Passive / adverse effects
  • Immunization, Passive / methods
  • Immunoglobulin G / immunology
  • Plasma / immunology
  • SARS-CoV-2 / immunology

Substances

  • Immunoglobulin G